Remove encroachments in vegetable market: NMC chief
As part of the ongoing sanitation drive, the Commissioner along with RDO Anusha inspected Anam Chenchu Subbareddy Vegetable Market at Madras bus stand centre in the city on Thursday.
He expressed angry on road margin traders for encroaching roads, causing inconvenience to public.
He ordered the officials to remove the encroachments immediately and to take steps to prevent reestablishment of shops in that area.
Later, the NMC chief inspected sanitary conditions in the market and shocked over the unhygienic conditions. He directed the Medical Health Officer to initiate action against three sanitary staff of that area for failing to do their duty. He also imposed penalty of Rs 5,000 to the traders for dumping waste on public road.
During interaction with the AC Vegetable Market association organisers, Commissioner Nandan suggested them to keep the market and surrounding areas clean.
MRO Shafi Malik and other officials were present.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
Allahabad HC stays fee hike for MBBS course by Hapur medical college
Agency: PTI Prayagraj, Aug 14 (PTI) The Allahabad High Court has stayed an increase in fee for the MBBS course by the GS Medical College in Hapur, and directed the state government and the college to file their reply within two weeks. The order was passed by Justice C D Singh on August 13 while hearing a petition filed by Aanya Porwal and 239 other MBBS students. The fee was increased mid-semester from Rs 11 lakh to 14 lakh. The counsel for the petitioners claimed the notification issued on July 5 by the state government was 'arbitrary" and 'without application of mind". The government, while issuing the aforesaid notification, failed to consider the other miscellaneous charges, which have already been enhanced during this session, the counsel argued. He said there was no reason to increase the fee for a second time in eight months, particularly when miscellaneous charges had already been deposited by the petitioners. The government's counsel submitted that it (fee hike) was done in accordance with the law, and there was no illegality or error in the impugned notification, saying the instant writ petition may be dismissed as devoid of any merit. The court said, 'Taking into consideration the submissions made by the learned counsel for the petitioners as well as the learned counsel for the respondent and the contents made in the writ petition, I am of the view that matter requires consideration." The court directed to put up the case on September 17, and till then the operation of the impugned notification dated July 5 shall be kept in abeyance. PTI COR RAJ ARI view comments First Published: August 14, 2025, 23:00 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Hans India
5 hours ago
- Hans India
AstraZeneca Pharma India's net profit slips 4 pc in Q1
Mumbai: AstraZeneca Pharma India Limited on Thursday reported a 4.12 per cent decline in net profit for the first quarter (Q1) of FY26, with earnings falling to Rs 55.8 crore from Rs 58.2 crore in the previous quarter (Q4 FY25). This dip came despite a strong rise in revenue from operations, which grew 9.56 per cent sequentially to Rs 526.3 crore from Rs 480.4 crore, according to its stock exchange filing. Other income saw a sharp decline of 30.43 per cent, dropping to Rs 11.2 crore from Rs 16.1 crore in Q4 FY25. However, total income rose 8.23 per cent to Rs 537.5 crore from Rs 496.6 crore, driven by solid operational performance. Total expenses increased by 12.12 per cent to Rs 462.4 crore, compared to Rs 412.4 crore in the previous quarter, the company stated in its regulatory filing. Bhavana Agrawal, Chief Financial Officer and Director of the Company, said the strong quarterly performance reflects the power of science-led innovation combined with disciplined execution. 'Each regulatory milestone brings us closer to transforming outcomes for patients living with chronic diseases. We remain focused on expanding our portfolio, strengthening partnerships, and ensuring that breakthrough medicines reach the people who need them most,' she added. Praveen Rao Akkinepally, Country President and Managing Director, said that delivering consistent growth across therapy areas reaffirms the strength of the company's 'Growth Through Innovation' strategy. 'These results are a testament to what is possible when science and purpose come together,' he noted. AstraZeneca, a global science-led biopharmaceutical company, focuses on the discovery, development, and commercialisation of prescription medicines, primarily in oncology, cardiovascular, renal and metabolism, respiratory, and rare diseases. The company operates in over 100 countries, with its medicines used by millions of patients worldwide. Completing 45 years in India, AstraZeneca Pharma India Limited is headquartered in Bengaluru and employs over 600 people across the country.
News18
6 hours ago
- News18
Cash On 'Delivery': This Country Is Paying Couples To Have Children; The Amount Will Blow Your Mind
The proposal, expected to secure cabinet approval soon, will extend the subsidy across multiple stages of IVF treatment, from the first attempt through the sixth In a bold move to counter its declining birth rate, Taiwan has announced a significant expansion of its financial support for couples seeking to have children through in-vitro fertilisation (IVF). The government will now offer up to Rs 6 lakh in assistance, more than double the current Rs 3 lakh, in an effort to make the costly procedure more accessible. The proposal, expected to secure cabinet approval soon, will extend the subsidy across multiple stages of IVF treatment, from the first attempt through the sixth. Until now, only the initial stage received such support. Officials said that the change addresses a key deterrent; IVF often requires several rounds to succeed, and many couples abandon the process due to escalating costs. Governments across the region are experimenting with incentives to boost birth rates. China, grappling with the long-term effects of its one-child policy, has introduced a national child-care subsidy starting January 2025 – 3,600 yuan (around Rs 43,000) annually for every child under three, with additional state-level benefits. Russia, facing a similar demographic crunch, offers Rs 6.65 lakh for a first child and Rs 8.70 lakh for a second. Some regions have gone further, extending payments even to schoolgirls who become pregnant. For Taiwan, officials hope that easing the financial burden of IVF will help reverse a trend that, if left unchecked, could reshape the nation's economy and workforce in the decades ahead. view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
